Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults, \>/= 18 years of age
Moderate to severe rheumatoid arthritis according to the revised (1987) American College of Rheumatology (ACR) criteria
Participants in whom the treating physician has made the decision to commence tocilizumab treatment (in accordance with the local label); this can include participants who have received tocilizumab treatment within 8 weeks prior to the enrollment visit
You may not be if
Participants who have received tocilizumab more than 8 weeks prior to the enrollment visit
Participants who have received treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with tocilizumab
History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis
Clareo Health | An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis
